• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Galectin Therapeutic (NQ: GALT )

    2.710 +0.060 (+2.26%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 63,919
    Open 2.670
    Bid (Size) 2.540 (1)
    Ask (Size) 2.700 (10)
    Prev. Close 2.650
    Today's Range 2.670 - 2.733
    52wk Range 1.555 - 4.268
    Shares Outstanding 59,395,805
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    GALT Stock Earnings: Galectin Therapeutics Misses EPS for Q2 2024
    GALT stock results show that Galectin Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Galectin Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
    Via Benzinga

    Performance

    YTD
    +55.75%
    +55.75%
    1 Month
    -5.24%
    -5.24%
    3 Month
    +19.91%
    +19.91%
    6 Month
    +11.07%
    +11.07%
    1 Year
    +42.63%
    +42.63%

    More News

    Read More
    GALT Stock Earnings: Galectin Therapeutics Misses EPS for Q1 2024
    Via InvestorPlace
    Galectin Therapeutics And 2 Other Penny Stocks Insiders Are Buying
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    GALT Stock Earnings: Galectin Therapeutics Meets EPS for Q4 2023
    Via InvestorPlace
    Galectin Therapeutics: Q3 Earnings Insights
    Via Benzinga
    Recap: Galectin Therapeutics Q1 Earnings
    Via Benzinga
    Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
    Via The Motley Fool
    More Personal Portfolio: Biotech, Commodities, And Gold
    Via Talk Markets
    Galectin Therapeutics And 3 Other Stocks Under $2 Insiders Are Buying
    Via Benzinga
    7 Short-Interest Stocks to Target for Explosive Gains
    Via InvestorPlace
    $7M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Buying
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Around $30 Million Bet On This Communication Services Stock? 4 Penny Stocks Insiders Are Buying
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Via InvestorPlace
    This Healthcare Stock Tumbled 43%; Here Are 88 Biggest Movers From Yesterday
    Via Benzinga
    62 Biggest Movers From Yesterday
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Stocks That Hit 52-Week Lows On Monday
    Via Benzinga
    Galectin Therapeutics: Q4 Earnings Insights
    Via Benzinga
    Stocks That Hit 52-Week Lows On Friday
    Via Benzinga
    Stocks That Hit 52-Week Lows On Tuesday
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.